Correction: Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations

QR Code

Correction: Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations

Enregistré dans:

Détails bibliographiques
Format:	article
Langue:	EN
Publié:	BMJ Publishing Group 2021
Sujets:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Accès en ligne:	https://doaj.org/article/891690c79fb34bd2a5beff02a9ca97bb
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics
par: Karachaliou N, et autres
Publié: (2014)

Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond
par: Suda K, et autres
Publié: (2013)

The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer
par: Barbara Melosky, et autres
Publié: (2021)

Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
par: Xiaoying Zhang
Publié: (2021)

Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR
par: Karan Seegobin, et autres
Publié: (2021)

Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of China
par: Gou LY, Wu YL
Publié: (2014)

Protein citrullination as a source of cancer neoantigens
par: Makoto Kobayashi, et autres
Publié: (2021)

Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity
par: Takahiro Yoshizawa, et autres
Publié: (2021)

Afatinib treatment in advanced non-small cell lung cancer
par: Hurwitz JL, et autres
Publié: (2011)

Non-small cell lung cancer: the era of targeted therapy
par: Antonoff MB, et autres
Publié: (2012)

Functional analysis of peripheral and intratumoral neoantigen-specific TCRs identified in a patient with melanoma
par: Melanie Boxberg, et autres
Publié: (2021)

EGFR mutations in patients with lung adenocarcinoma in southwest China: are G719S/A and L861Q more likely detected in tumors derived from smokers?
par: Wang QS, et autres
Publié: (2013)

Pemetrexed in maintenance treatment of advanced non-squamous non-small-cell lung cancer
par: Minami S, et autres
Publié: (2015)

High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4+ and CD8+ neoantigen-specific T cells to promote antitumor immunity
par: Rosmely Hernandez, et autres
Publié: (2021)

Epiregulin as a therapeutic target in non-small-cell lung cancer
par: Sunaga N, et autres
Publié: (2015)

Emerging treatment options in the management of non-small cell lung cancer
par: Filosso PL, et autres
Publié: (2011)

Non-small-cell lung carcinoma: role of the Notch signaling pathway
par: Barse L, et autres
Publié: (2015)

Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies
par: Andrew Wallace, et autres
Publié: (2021)

A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer
par: Igawa S, et autres
Publié: (2021)

Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer
par: Stasi I, et autres
Publié: (2014)

Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer
par: Burns MW, et autres
Publié: (2015)

First-line treatment of advanced ALK-positive non-small-cell lung cancer
par: Gandhi S, et autres
Publié: (2015)

New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer
par: Weise AM, et autres
Publié: (2014)

Combination chemotherapy of gemcitabine and vinorelbine for pretreated non-small- cell lung cancer: a retrospective study
par: Minami S, et autres
Publié: (2015)

Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer
par: Berghmans T, et autres
Publié: (2012)

A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer
par: Natalia J. Gurule, et autres
Publié: (2021)

Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study
par: Taichi Miyawaki, et autres
Publié: (2021)

Targeting MERTK and AXL in <i>EGFR</i> Mutant Non-Small Cell Lung Cancer
par: Dan Yan, et autres
Publié: (2021)

Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence
par: Rothschild SI
Publié: (2014)

Clinical characteristics and outcomes of Chinese patients with KRAS‐mutant non‐small cell lung cancer after chemotherapy
par: Yawen Zheng, et autres
Publié: (2021)

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M
par: Yurong Wang, et autres
Publié: (2021)

Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient
par: Maurício Fernando Silva Almeida Ribeiro, et autres
Publié: (2021)

Construction of a circRNA-miRNA-mRNA Regulated Pathway Involved in EGFR-TKI Lung Adenocarcinoma Resistance
par: Chenyue Dai MM, et autres
Publié: (2021)

Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer
par: Takeda M, et autres
Publié: (2011)

Robotic stereotactic body radiation therapy for elderly medically inoperable early-stage non-small cell lung cancer
par: Karam SD, et autres
Publié: (2013)

Identification and Integrate Analysis of Key Biomarkers for Diagnosis and Prognosis of Non-Small Cell Lung Cancer Based on Bioinformatics Analysis
par: Ke Gong MBBS, et autres
Publié: (2021)

Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
par: Marianne Oulhen, et autres
Publié: (2021)

Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development
par: Ke Cheng, et autres
Publié: (2021)

Possibility of brigatinib‐based therapy, or chemotherapy plus anti‐angiogenic treatment after resistance of osimertinib harboring EGFR T790M‐cis‐C797S mutations in lung adenocarcinoma patients
par: Yaning Yang, et autres
Publié: (2021)

Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT)
par: Alfredo Addeo, et autres
Publié: (2021)